Seattle Genetics Stock Price, News & Analysis (NASDAQ:SGEN)

$54.48 -0.37 (-0.67 %)
(As of 02/20/2018 04:42 AM ET)
Previous Close$54.85
Today's Range$54.27 - $55.81
52-Week Range$45.31 - $71.32
Volume965,100 shs
Average Volume1.40 million shs
Market Capitalization$7.84 billion
P/E Ratio-61.21
Dividend YieldN/A
Beta2.08

About Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics logoSeattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:SGEN
CUSIP81257810
Phone+1-425-5274000

Debt

Debt-to-Equity RatioN/A
Current Ratio3.45%
Quick Ratio3.09%

Price-To-Earnings

Trailing P/E Ratio-61.2134831460674
Forward P/E Ratio-34.26
P/E GrowthN/A

Sales & Book Value

Annual Sales$482.25 million
Price / Sales17.84
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book11.57

Profitability

Trailing EPS($0.89)
Net Income$-125,530,000.00
Net Margins-26.03%
Return on Equity-32.49%
Return on Assets-24.96%

Miscellaneous

Employees890
Outstanding Shares157,950,000

Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

How were Seattle Genetics' earnings last quarter?

Seattle Genetics, Inc. (NASDAQ:SGEN) posted its earnings results on Tuesday, February, 6th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.02. The biotechnology company earned $129.61 million during the quarter, compared to analyst estimates of $123.99 million. Seattle Genetics had a negative net margin of 26.03% and a negative return on equity of 32.49%. Seattle Genetics's revenue for the quarter was up 23.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.39) earnings per share. View Seattle Genetics' Earnings History.

When will Seattle Genetics make its next earnings announcement?

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Seattle Genetics.

Where is Seattle Genetics' stock going? Where will Seattle Genetics' stock price be in 2018?

19 analysts have issued 12-month price objectives for Seattle Genetics' stock. Their forecasts range from $48.00 to $75.00. On average, they anticipate Seattle Genetics' share price to reach $64.00 in the next twelve months. View Analyst Ratings for Seattle Genetics.

What are Wall Street analysts saying about Seattle Genetics stock?

Here are some recent quotes from research analysts about Seattle Genetics stock:

  • 1. HC Wainwright analysts commented, "to Approval on June 25 PDUFA; Raise PT to $31 Stock Data 02/06/2018 Price $10.79 Exchange NASDAQ Price Target $31.00 52-Week High $27.79 52-Week Low $9.88 Enterprise Value (M) $282.5 Market Cap (M) $457 Public Market Float (M) 23.8 Shares Outstanding (M) 42.4 3 Month Avg Volume 1,154,580 Short Interest (M) 10.70 Shares Outstanding (M): Figure shown is as of November 2, 2017. Balance Sheet Metrics Cash (M) $199.4 Total Debt (M) $24.9 Total Cash/Share $4.70 Book Value/Share $3.55 Cash (M): Amount shown is as of September 30, 2017. EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.66) (0.93)A (0.79) 2Q (0.87) (0.78)A (0.82) 3Q (0.41) (0.85)A (0.76) 4Q (1.04) (0.83) (0.75) FY (3.00) (3.10) (3.11) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 5.8 7.5A 0.6 2Q 9.1 1.3A 0.7 3Q 16.0 0.6A 1.2 4Q 10.7 0.8 1.8 FY 41.8 10.1 4.3 30 25 20 15 10 5 FEB- 17 J UN- 17 OCT- 17 FEB- 18 6 5 4 3 2 1 0 Vol. (mil) Price Manufacturing overhang lifted with VAI status at McPherson site." (2/7/2018)
  • 2. JPMorgan Chase & Co. analysts commented, "Forecasts; We Expect Shares to Be Pressured Monday morning, ViewRay announced preliminary 2017 revenue of $34M and 4Q17 orders of $34M. Both metrics were significantly below our expectations. With so much investor focus on system sales and conversion to revenue, we expect VRAY to trade off today.   The company recognized revenue on 4 MRIdian Linac Systems in the quarter. For the full year, VRAY announced total revenue of $34M. We had modeled $42.5M in revenue for the full year. Management noted that revenue recognition was delayed on one of the 5 systems shipped or installed in the quarter. That delay should result in $7M in revenue recognized in a later period. Investors have been eager to see backlog convert to revenue and this miss is likely to disappoint.   In the quarter, VRAY received $34M in new MRIdian Linac System orders, less than the $48M we had forecasted. That order number is lower the company’s orders in the second quarter and likely does not demonstrate enough of an uptick in momentum from the $29.9M order reported in 3Q." (1/9/2018)
  • 3. Cann analysts commented, "Seattle Genetics and Astellas Pharma announced today dosing of the first patient in EV-103 study in combination with two different checkpoint inhibitors, for first- or second-line treatment of patients with locally advanced or metastatic urothelial cancer. We have not included any sales or earnings from enfortumab vedotin by 2021 due to its stage of development, but we are encouraged by this development program. Our financial outlook for Seattle Genetics’ revenue remains unchanged for 2017-21." (11/8/2017)
  • 4. According to Zacks Investment Research, "Seattle Genetics beat both earnings and sales estimates in the third quarter of 2017. Concurrently, the company raised 2017 revenues outlook.The company has upped its guidance for 2017 driven by a robust performance of Adcetris in the first half. We are also encouraged by the company’s efforts to expand the drug’s label. The company’s collaboration with Takeda for the global development and commercialization of Adcetris is encouraging. However, dependence on one product – Adcetris– for growth has its inherent risks. The recent label expansion of Merck’s Keytruda in the lymphoma indication is likely to increase competition. Though the company has multiple candidates in its pipeline, most of them are in early stages of development. The company’s shares have outperformed the industry year to date." (11/6/2017)

Who are some of Seattle Genetics' key competitors?

Who are Seattle Genetics' key executives?

Seattle Genetics' management team includes the folowing people:

  • Clay B. Siegall Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 56)
  • Todd E. Simpson, Chief Financial Officer (Age 56)
  • Jean I. Liu J.D., Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary (Age 48)
  • Darren S. Cline, Executive Vice President - Commercial (Age 52)
  • Jonathan G. Drachman M.D., Chief Medical Officer, Executive Vice President - Research and Development (Age 55)
  • Vaughn B. Himes Ph.D., Chief Technical Officer (Age 56)
  • Felix J. Baker Ph.D., Lead Independent Director (Age 47)
  • Srinivas Akkaraju M.D. Ph.D., Independent Director (Age 49)
  • David W. Gryska, Independent Director (Age 61)
  • Marc E. Lippman M.D., Independent Director (Age 72)

Who owns Seattle Genetics stock?

Seattle Genetics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.99%), Goldman Sachs Group Inc. (1.59%), Redmile Group LLC (0.74%), Wasatch Advisors Inc. (0.68%), Pinnacle Associates Ltd. (0.60%) and Geode Capital Management LLC (0.56%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, Eric Dobmeier, Felix Baker, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.

Who sold Seattle Genetics stock? Who is selling Seattle Genetics stock?

Seattle Genetics' stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Deutsche Bank AG, TIAA CREF Investment Management LLC, Renaissance Technologies LLC, Spark Investment Management LLC, Pinnacle Associates Ltd., First Trust Advisors LP and Wasatch Advisors Inc.. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.

Who bought Seattle Genetics stock? Who is buying Seattle Genetics stock?

Seattle Genetics' stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Millennium Management LLC, BlackRock Inc., Two Sigma Investments LP, UBS Asset Management Americas Inc., Candriam Luxembourg S.C.A., LPL Financial LLC and Two Sigma Advisers LP. Company insiders that have bought Seattle Genetics stock in the last two years include Bros Advisors Lp Baker and Felix Baker. View Insider Buying and Selling for Seattle Genetics.

How do I buy Seattle Genetics stock?

Shares of Seattle Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seattle Genetics' stock price today?

One share of Seattle Genetics stock can currently be purchased for approximately $54.48.

How big of a company is Seattle Genetics?

Seattle Genetics has a market capitalization of $7.84 billion and generates $482.25 million in revenue each year. The biotechnology company earns $-125,530,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Seattle Genetics employs 890 workers across the globe.

How can I contact Seattle Genetics?

Seattle Genetics' mailing address is 21823 30th Dr SE, BOTHELL, WA 98021-3907, United States. The biotechnology company can be reached via phone at +1-425-5274000 or via email at [email protected]


MarketBeat Community Rating for Seattle Genetics (SGEN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  354 (Vote Outperform)
Underperform Votes:  419 (Vote Underperform)
Total Votes:  773
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Seattle Genetics (NASDAQ:SGEN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldHoldHold
Consensus Rating Score: 2.532.452.382.21
Ratings Breakdown: 0 Sell Rating(s)
9 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
9 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $64.00$63.20$62.93$61.85
Price Target Upside: 22.72% upside15.58% upside8.58% upside32.07% upside

Seattle Genetics (NASDAQ:SGEN) Consensus Price Target History

Price Target History for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ:SGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018JPMorgan Chase & Co.UpgradeNeutral -> Overweight$60.00LowView Rating Details
2/7/2018Bank of AmericaLower Price TargetNeutral -> Neutral$70.00 -> $68.00LowView Rating Details
2/7/2018Needham & Company LLCReiterated RatingBuy -> Buy$72.00 -> $74.00HighView Rating Details
2/7/2018SunTrust BanksReiterated RatingHold$60.00HighView Rating Details
2/7/2018HC WainwrightReiterated RatingBuyHighView Rating Details
1/8/2018Cantor FitzgeraldSet Price TargetHold$50.00LowView Rating Details
1/2/2018OppenheimerReiterated RatingHoldHighView Rating Details
12/11/2017CowenReiterated RatingHold$54.00LowView Rating Details
11/13/2017Royal Bank of CanadaBoost Price TargetOutperform -> Outperform$68.00 -> $69.00N/AView Rating Details
11/8/2017CannInitiated CoverageHoldN/AView Rating Details
10/31/2017Morgan StanleyBoost Price TargetOverweight$64.00 -> $69.00N/AView Rating Details
10/26/2017Jefferies GroupReiterated RatingBuy$53.00N/AView Rating Details
10/23/2017GuggenheimReiterated RatingBuy -> Buy$72.00N/AView Rating Details
10/20/2017BarclaysUpgradeEqual Weight -> Overweight$60.00 -> $70.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral -> Neutral$64.00N/AView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/27/2017Piper Jaffray CompaniesReiterated RatingNeutral$48.00HighView Rating Details
4/7/2017Leerink SwannBoost Price TargetOutperform$70.00 -> $74.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
2/13/2017Credit Suisse GroupBoost Price TargetNeutral$62.00 -> $66.00N/AView Rating Details
1/5/2017Maxim GroupReiterated RatingReduceN/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Seattle Genetics (NASDAQ:SGEN) Earnings History and Estimates Chart

Earnings by Quarter for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ SGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018($0.42)N/AView Earnings Details
2/6/2018Q4 2017($0.43)($0.41)$123.99 million$129.61 millionViewListenView Earnings Details
10/26/2017Q3 2017($0.42)($0.19)$112.76 million$135.29 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.42)($0.39)$105.92 million$108.20 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.42)$103.23 million$109.10 millionViewN/AView Earnings Details
2/9/2017Q416($0.34)($0.39)$106.49 million$105.30 millionViewListenView Earnings Details
10/27/2016Q316($0.29)($0.23)$4.34 million$106.30 millionViewListenView Earnings Details
7/26/2016Q216($0.32)($0.23)$94.56 million$95.40 millionViewListenView Earnings Details
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.39)($0.45)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.36)($0.30)ViewN/AView Earnings Details
2/8/2011Q4 2010($0.38)($0.34)ViewN/AView Earnings Details
11/1/2010Q3 2010($0.35)($0.34)ViewN/AView Earnings Details
7/27/2010Q2 2010($0.01)($0.08)ViewN/AView Earnings Details
4/27/2010Q1 2010$0.04$0.11ViewN/AView Earnings Details
2/9/2010Q4 2009($0.23)($0.12)ViewN/AView Earnings Details
10/22/2009Q3 2009($0.26)($0.21)ViewN/AView Earnings Details
7/23/2009Q2 2009($0.29)($0.26)ViewN/AView Earnings Details
4/23/2009Q1 2009($0.28)($0.33)ViewN/AView Earnings Details
2/5/2009Q4 2008($0.30)($0.38)ViewN/AView Earnings Details
10/23/2008Q3 2008($0.26)($0.27)ViewN/AView Earnings Details
7/22/2008Q2 2008($0.26)($0.20)ViewN/AView Earnings Details
4/24/2008Q1 2008($0.18)($0.22)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.23)($0.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Seattle Genetics (NASDAQ:SGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.68)
2019 EPS Consensus Estimate: ($0.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.49)($0.41)($0.45)
Q2 20184($0.50)($0.38)($0.43)
Q3 20184($0.49)($0.30)($0.40)
Q4 20184($0.51)($0.26)($0.41)
Q1 20191($0.31)($0.31)($0.31)
Q2 20191($0.21)($0.21)($0.21)
Q3 20191($0.14)($0.14)($0.14)
Q4 20191($0.07)($0.07)($0.07)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Seattle Genetics (NASDAQ:SGEN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Seattle Genetics (NASDAQ SGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 34.70%
Institutional Ownership Percentage: 90.99%
Insider Trades by Quarter for Seattle Genetics (NASDAQ:SGEN)
Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ SGEN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2018Clay B. SiegallInsiderSell18,832$49.75$936,892.00View SEC Filing  
2/1/2018Bros. Advisors Lp BakerDirectorBuy3,846,153$52.00$199,999,956.00View SEC Filing  
1/11/2018Clay B. SiegallInsiderSell18,832$51.71$973,802.72View SEC Filing  
12/11/2017Clay B. SiegallInsiderSell18,832$55.40$1,043,292.80View SEC Filing  
12/4/2017Eric DobmeierCOOSell3,729$58.75$219,078.75View SEC Filing  
11/30/2017Vaughn B. HimesInsiderSell10,000$59.97$599,700.00View SEC Filing  
11/17/2017Eric DobmeierCOOSell35,000$58.25$2,038,750.00View SEC Filing  
11/15/2017Eric DobmeierCOOSell9,600$57.80$554,880.00View SEC Filing  
11/15/2017Marc E. LippmanDirectorSell3,000$58.07$174,210.00View SEC Filing  
11/10/2017Clay B. SiegallInsiderSell18,832$58.00$1,092,256.00View SEC Filing  
11/1/2017Todd E. SimpsonCFOSell39,385$60.91$2,398,940.35View SEC Filing  
10/11/2017Clay B SiegallInsiderSell18,832$61.18$1,152,141.76View SEC Filing  
9/11/2017Clay B. SiegallInsiderSell18,832$53.49$1,007,323.68View SEC Filing  
9/8/2017Vaughn B. HimesInsiderSell10,000$53.22$532,200.00View SEC Filing  
9/6/2017Darren S. ClineEVPSell5,024$51.94$260,946.56View SEC Filing  
9/6/2017Todd E. SimpsonCFOSell9,638$52.00$501,176.00View SEC Filing  
8/31/2017Darren S. ClineEVPSell7,569$52.51$397,448.19View SEC Filing  
8/31/2017Eric DobmeierCOOSell25,000$52.24$1,306,000.00View SEC Filing  
8/28/2017Clay B. SiegallCEOSell25,506$47.89$1,221,482.34View SEC Filing  
8/28/2017Darren S. ClineEVPSell1,788$47.89$85,627.32View SEC Filing  
8/28/2017Eric DobmeierCOOSell5,343$47.89$255,876.27View SEC Filing  
8/28/2017Jonathan G. DrachmanCMOSell8,502$47.89$407,160.78View SEC Filing  
8/28/2017Todd E. SimpsonCFOSell4,937$47.89$236,432.93View SEC Filing  
8/28/2017Vaughn B. HimesInsiderSell6,377$47.89$305,394.53View SEC Filing  
8/24/2017Jonathan G. DrachmanCMOSell10,000$47.54$475,400.00View SEC Filing  
8/7/2017Clay B. SiegallInsiderSell10,413$48.91$509,299.83View SEC Filing  
8/7/2017Darren S. ClineEVPSell6,000$49.19$295,140.00View SEC Filing  
7/27/2017Jonathan G. DrachmanCMOSell10,000$54.54$545,400.00View SEC Filing  
7/5/2017Clay B. SiegallCEOSell10,423$51.98$541,787.54View SEC Filing  
6/22/2017Jonathan G DrachmanCMOSell10,000$64.01$640,100.00125,204View SEC Filing  
6/5/2017Clay B. SiegallInsiderSell10,423$65.21$679,683.83View SEC Filing  
4/5/2017Clay B SiegallInsiderSell14,465$62.99$911,150.35646,858View SEC Filing  
3/31/2017Vaughn B HimesInsiderSell10,000$62.75$627,500.00161,283View SEC Filing  
3/6/2017Clay B SiegallCEOSell14,465$68.04$984,198.60646,858View SEC Filing  
2/6/2017Clay B SiegallInsiderSell14,465$61.54$890,176.10640,477View SEC Filing  
1/6/2017Clay B. SiegallInsiderSell14,465$57.89$837,378.85View SEC Filing  
12/13/2016Darren S. ClineEVPSell10,000$63.38$633,800.00View SEC Filing  
12/8/2016Eric DobmeierCOOSell12,500$65.92$824,000.00View SEC Filing  
12/7/2016Vaughn B. HimesInsiderSell30,000$65.32$1,959,600.00View SEC Filing  
11/8/2016Felix BakerDirectorBuy382,500$59.36$22,705,200.00View SEC Filing  
11/7/2016Clay B. SiegallCEOSell14,465$58.43$845,189.95View SEC Filing  
11/7/2016Marc E. LippmanDirectorSell1,000$57.75$57,750.00View SEC Filing  
11/3/2016Felix BakerDirectorBuy1,030,629$56.13$57,849,205.77View SEC Filing  
11/1/2016Jonathan G. DrachmanCMOSell3,418$51.74$176,847.32View SEC Filing  
10/6/2016Clay B. SiegallInsiderSell14,465$54.41$787,040.65View SEC Filing  
9/22/2016Jonathan G DrachmanCMOSell2,249$56.75$127,630.75115,504View SEC Filing  
9/14/2016Eric DobmeierCOOSell22,918$54.04$1,238,488.72View SEC Filing  
9/13/2016Felix BakerDirectorBuy447,311$50.71$22,683,140.81View SEC Filing  
9/8/2016Clay B. SiegallInsiderSell31,269$50.08$1,565,951.52View SEC Filing  
9/8/2016Felix BakerDirectorBuy414,016$48.43$20,050,794.88View SEC Filing  
8/23/2016Eric DobmeierCOOSell12,589$48.00$604,272.00View SEC Filing  
8/22/2016Clay B. SiegallInsiderSell23,381$46.59$1,089,320.79View SEC Filing  
8/22/2016Eric DobmeierCOOSell5,411$46.59$252,098.49View SEC Filing  
8/22/2016Vaughn B. HimesEVPSell3,991$46.59$185,940.69View SEC Filing  
8/8/2016Clay B. SiegallInsiderSell11,660$47.19$550,235.40View SEC Filing  
7/27/2016Clay B. SiegallInsiderSell4,042$45.20$182,698.40View SEC Filing  
7/6/2016Clay B. SiegallCEOSell7,618$40.56$308,986.08View SEC Filing  
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97566,538View SEC Filing  
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.6242,747View SEC Filing  
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60563,883View SEC Filing  
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00562,815View SEC Filing  
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00562,815View SEC Filing  
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88563,733View SEC Filing  
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00556,915View SEC Filing  
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16563,733View SEC Filing  
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72560,397View SEC Filing  
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82560,397View SEC Filing  
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.2538,783,387View SEC Filing  
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70107,511View SEC Filing  
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.4438,671,506View SEC Filing  
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.5738,671,506View SEC Filing  
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.3637,454,776View SEC Filing  
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18107,511View SEC Filing  
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94107,511View SEC Filing  
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00107,511View SEC Filing  
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58107,511View SEC Filing  
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.0076,212View SEC Filing  
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80556,115View SEC Filing  
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52107,504View SEC Filing  
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20556,115View SEC Filing  
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.9237,713View SEC Filing  
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80107,504View SEC Filing  
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00107,504View SEC Filing  
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.0080,888View SEC Filing  
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56107,504View SEC Filing  
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.0023,950View SEC Filing  
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52643,588View SEC Filing  
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40611,323View SEC Filing  
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16611,323View SEC Filing  
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08611,323View SEC Filing  
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.6243,482View SEC Filing  
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.9698,340View SEC Filing  
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.2482,724View SEC Filing  
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50179,874View SEC Filing  
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.9476,212View SEC Filing  
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.7776,997View SEC Filing  
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00955,696View SEC Filing  
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00955,696View SEC Filing  
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.2077,833View SEC Filing  
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.7549,911View SEC Filing  
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.4876,997View SEC Filing  
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.1976,997View SEC Filing  
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35155,395View SEC Filing  
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.231,124,558View SEC Filing  
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48127,620View SEC Filing  
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.7646,307View SEC Filing  
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Seattle Genetics (NASDAQ SGEN) News Headlines

Source:
DateHeadline
Seattle Genetics (SGEN) Given "Buy" Rating at HC WainwrightSeattle Genetics (SGEN) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - February 20 at 12:58 AM
Seattle Genetics (SGEN) Given Buy Rating at Needham & Company LLCSeattle Genetics (SGEN) Given Buy Rating at Needham & Company LLC
www.americanbankingnews.com - February 19 at 11:54 PM
Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting PeriodSeattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period
finance.yahoo.com - February 16 at 8:41 AM
Reviewing Seattle Genetics (SGEN) and Cellectis (CLLS)Reviewing Seattle Genetics (SGEN) and Cellectis (CLLS)
www.americanbankingnews.com - February 16 at 5:18 AM
PharmaMar octroie des charges utiles dorigine marine entièrement synthétiques sous licence à Seattle Genetics pour les utiliser dans des conjugués de médicamentsPharmaMar octroie des charges utiles d'origine marine entièrement synthétiques sous licence à Seattle Genetics pour les utiliser dans des conjugués de médicaments
www.prnewswire.com - February 16 at 4:32 AM
PharmaMar concede in licenza a Seattle Genetics composti sintetici di origine marina per lutilizzo in coniugati farmaceuticiPharmaMar concede in licenza a Seattle Genetics composti sintetici di origine marina per l'utilizzo in coniugati farmaceutici
www.prnewswire.com - February 16 at 12:44 AM
PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics ...PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics ...
www.prnewswire.com - February 15 at 5:00 PM
Seattle Genetics Inc (SGEN) Files 10-K for the Fiscal Year Ended on December 31, 2017Seattle Genetics Inc (SGEN) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 15 at 8:20 AM
Seattle Genetics (SGEN) Upgraded to "Overweight" at JPMorgan Chase & Co.Seattle Genetics (SGEN) Upgraded to "Overweight" at JPMorgan Chase & Co.
www.americanbankingnews.com - February 15 at 12:52 AM
Here's Why Pieris Pharmaceuticals Inc. Is TankingHere's Why Pieris Pharmaceuticals Inc. Is Tanking
finance.yahoo.com - February 14 at 5:10 PM
Clay B. Siegall Sells 18,832 Shares of Seattle Genetics, Inc. (SGEN) StockClay B. Siegall Sells 18,832 Shares of Seattle Genetics, Inc. (SGEN) Stock
www.americanbankingnews.com - February 13 at 9:10 PM
Wired News – Pieris Pharma Collaborated with Seattle Genetics to Develop Immuno-Oncology TreatmentsWired News – Pieris Pharma Collaborated with Seattle Genetics to Develop Immuno-Oncology Treatments
finance.yahoo.com - February 12 at 9:33 AM
SunTrust Banks Weighs in on Seattle Genetics, Inc.s Q3 2018 Earnings (SGEN)SunTrust Banks Weighs in on Seattle Genetics, Inc.'s Q3 2018 Earnings (SGEN)
www.americanbankingnews.com - February 9 at 11:36 AM
Seattle Genetics Is Growing Up Any Way It CanSeattle Genetics Is Growing Up Any Way It Can
finance.yahoo.com - February 9 at 9:36 AM
Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology CollaborationPieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration
finance.yahoo.com - February 9 at 9:36 AM
Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology CollaborationSeattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
finance.yahoo.com - February 9 at 9:36 AM
Leerink Swann Analysts Reduce Earnings Estimates for Seattle Genetics, Inc. (SGEN)Leerink Swann Analysts Reduce Earnings Estimates for Seattle Genetics, Inc. (SGEN)
www.americanbankingnews.com - February 9 at 8:52 AM
Seattle Genetics, Inc. Expected to Post Q1 2018 Earnings of ($0.46) Per Share (SGEN)Seattle Genetics, Inc. Expected to Post Q1 2018 Earnings of ($0.46) Per Share (SGEN)
www.americanbankingnews.com - February 9 at 8:30 AM
Research Analysts Offer Predictions for Seattle Genetics, Inc.s Q1 2018 Earnings (SGEN)Research Analysts Offer Predictions for Seattle Genetics, Inc.'s Q1 2018 Earnings (SGEN)
www.americanbankingnews.com - February 9 at 7:52 AM
Seattle Genetics, Inc. (SGEN) Expected to Earn Q1 2019 Earnings of ($0.31) Per ShareSeattle Genetics, Inc. (SGEN) Expected to Earn Q1 2019 Earnings of ($0.31) Per Share
www.americanbankingnews.com - February 8 at 3:52 PM
SunTrust Banks Comments on Seattle Genetics, Inc.s Q1 2018 Earnings (SGEN)SunTrust Banks Comments on Seattle Genetics, Inc.'s Q1 2018 Earnings (SGEN)
www.americanbankingnews.com - February 8 at 9:20 AM
Today’s Research Reports on Stocks to Watch: Array BioPharma Inc. and Seattle GeneticsToday’s Research Reports on Stocks to Watch: Array BioPharma Inc. and Seattle Genetics
finance.yahoo.com - February 8 at 8:32 AM
Seattle Genetics (SGEN) Q4 Earnings & Revenues Top EstimatesSeattle Genetics (SGEN) Q4 Earnings & Revenues Top Estimates
finance.yahoo.com - February 8 at 8:32 AM
Bank of America Cuts Seattle Genetics (SGEN) Price Target to $68.00Bank of America Cuts Seattle Genetics (SGEN) Price Target to $68.00
www.americanbankingnews.com - February 7 at 1:30 PM
Seattle Genetics reports 4Q lossSeattle Genetics reports 4Q loss
finance.yahoo.com - February 7 at 9:40 AM
Seattle Genetics Reports Fourth Quarter and Year 2017 Financial ResultsSeattle Genetics Reports Fourth Quarter and Year 2017 Financial Results
finance.yahoo.com - February 7 at 9:40 AM
Seattle Genetics (SGEN) Issues  Earnings Results, Beats Estimates By $0.02 EPSSeattle Genetics (SGEN) Issues Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - February 7 at 9:22 AM
SunTrust Banks Reaffirms "Hold" Rating for Seattle Genetics (SGEN)SunTrust Banks Reaffirms "Hold" Rating for Seattle Genetics (SGEN)
www.americanbankingnews.com - February 7 at 8:36 AM
Seattle Genetics, Inc. (SGEN) Director Bros. Advisors Lp Baker Purchases 3,846,153 SharesSeattle Genetics, Inc. (SGEN) Director Bros. Advisors Lp Baker Purchases 3,846,153 Shares
www.americanbankingnews.com - February 5 at 6:26 PM
Why Earnings Season Could Be Great for Seattle Genetics (SGEN)Why Earnings Season Could Be Great for Seattle Genetics (SGEN)
finance.yahoo.com - February 5 at 9:32 AM
Seattle Genetics, Inc. (SGEN) Expected to Announce Quarterly Sales of $109.73 MillionSeattle Genetics, Inc. (SGEN) Expected to Announce Quarterly Sales of $109.73 Million
www.americanbankingnews.com - February 5 at 2:26 AM
Seattle Genetics: A Buy After Brilliant Acquisition - Seeking AlphaSeattle Genetics: A Buy After Brilliant Acquisition - Seeking Alpha
seekingalpha.com - February 4 at 9:29 AM
-$0.44 Earnings Per Share Expected for Seattle Genetics, Inc. (SGEN) This Quarter-$0.44 Earnings Per Share Expected for Seattle Genetics, Inc. (SGEN) This Quarter
www.americanbankingnews.com - February 3 at 7:18 PM
Today’s Research Reports on Trending Tickers: Nektar Therapeutics and Seattle Genetics, Inc.Today’s Research Reports on Trending Tickers: Nektar Therapeutics and Seattle Genetics, Inc.
finance.yahoo.com - February 2 at 9:35 AM
Wainwright bullish on Seattle Genetics on tucatinib prospects, sees 34% upsideWainwright bullish on Seattle Genetics on tucatinib prospects, sees 34% upside
seekingalpha.com - February 1 at 1:57 PM
Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by SanofiBiotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi
finance.yahoo.com - February 1 at 9:38 AM
Seattle Genetics Announces Pricing of Public Offering of Common StockSeattle Genetics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - February 1 at 9:38 AM
Seattle Genetics (SGEN) to Acquire Cascadian Therapeutics (CASC) for $10/ShareSeattle Genetics (SGEN) to Acquire Cascadian Therapeutics (CASC) for $10/Share
www.streetinsider.com - January 31 at 4:04 PM
Why Cascadian Therapeutics Shares Are SkyrocketingWhy Cascadian Therapeutics Shares Are Skyrocketing
finance.yahoo.com - January 31 at 4:04 PM
Here's Why Cascadian Therapeutics Jumped Up to 73.1% TodayHere's Why Cascadian Therapeutics Jumped Up to 73.1% Today
finance.yahoo.com - January 31 at 4:04 PM
Why Cascadian Therapeutics Inc (USA) Is Today’s Best Biotech StockWhy Cascadian Therapeutics Inc (USA) Is Today’s Best Biotech Stock
finance.yahoo.com - January 31 at 4:04 PM
Seattle Genetics (SGEN) Scheduled to Post Earnings on WednesdaySeattle Genetics (SGEN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - January 31 at 2:48 AM
Seattle Genetics, Inc. (SGEN) Given Consensus Recommendation of "Hold" by BrokeragesSeattle Genetics, Inc. (SGEN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 30 at 5:44 AM
Seattle Genetics Adcetris Gets EU Nod For Label ExpansionSeattle Genetics' Adcetris Gets EU Nod For Label Expansion
www.benzinga.com - January 24 at 10:10 AM
Seattle Genetics (SGEN) Shares Cross Above 200 DMASeattle Genetics (SGEN) Shares Cross Above 200 DMA
www.nasdaq.com - January 24 at 10:10 AM
Seattle Genetics, Inc. (SGEN) to Post FY2022 Earnings of $2.55 Per Share, SunTrust Banks ForecastsSeattle Genetics, Inc. (SGEN) to Post FY2022 Earnings of $2.55 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - January 22 at 3:22 PM
Seattle Genetics (SGEN) Announces ADCETRIS Receives EC Approval for CD30-Positive Cutaneous T-Cell ... - StreetInsider.comSeattle Genetics (SGEN) Announces ADCETRIS Receives EC Approval for CD30-Positive Cutaneous T-Cell ... - StreetInsider.com
www.streetinsider.com - January 22 at 1:06 PM
Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic TherapySeattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy
finance.yahoo.com - January 22 at 1:06 PM
 Analysts Expect Seattle Genetics, Inc. (SGEN) Will Post Quarterly Sales of $109.73 Million Analysts Expect Seattle Genetics, Inc. (SGEN) Will Post Quarterly Sales of $109.73 Million
www.americanbankingnews.com - January 19 at 2:58 AM
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018
finance.yahoo.com - January 18 at 9:38 AM

SEC Filings

Seattle Genetics (NASDAQ:SGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Seattle Genetics (NASDAQ:SGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Seattle Genetics (NASDAQ SGEN) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.